These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9593166)

  • 1. In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers.
    Fuchs PC; Barry AL; Brown SD
    Antimicrob Agents Chemother; 1998 May; 42(5):1274-7. PubMed ID: 9593166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.
    Cohen MA; Huband MD; Gage JW; Yoder SL; Roland GE; Gracheck SJ
    J Antimicrob Chemother; 1997 Aug; 40(2):205-11. PubMed ID: 9301985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of gemifloxacin against contemporary clinical bacterial isolates from eleven North American medical centers, and assessment of disk diffusion test interpretive criteria.
    Fuchs PC; Barry AL; Brown SD
    Diagn Microbiol Infect Dis; 2000 Dec; 38(4):243-53. PubMed ID: 11146251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacterial eradication by clinafloxacin, CI-990, and ciprofloxacin employing MBC test, in-vitro time-kill and in-vivo time-kill studies.
    Cohen MA; Huband MD; Yoder SL; Gage JW; Roland GE
    J Antimicrob Chemother; 1998 Jun; 41(6):605-14. PubMed ID: 9687098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals.
    Deshpande LM; Diekema DJ; Jones RN
    Diagn Microbiol Infect Dis; 1999 Sep; 35(1):81-8. PubMed ID: 10529885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative activities of clinafloxacin against gram-positive and -negative bacteria.
    Ednie LM; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 May; 42(5):1269-73. PubMed ID: 9593165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests.
    Barry AL; Fuchs PC; Brown SD
    Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):305-9. PubMed ID: 10385024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates.
    Marshall SA; Jones RN; Murray PR; Washington JA; Allen SD; Gerlach EH; Erwin ME
    J Antimicrob Chemother; 1993 Dec; 32(6):877-84. PubMed ID: 8144428
    [No Abstract]   [Full Text] [Related]  

  • 9. Multicenter in vitro comparative study of fluoroquinolones against 25,129 gram-positive and gram-negative clinical isolates.
    Prosser BL; Beskid G
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):33-45. PubMed ID: 7789095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS; Ahlén S
    Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
    Bauernfeind A
    J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interpretive criteria for DU-6859a disk diffusion tests using 5-micrograms disks.
    Jones RN; Johnson DM; Erwin ME
    Diagn Microbiol Infect Dis; 1994 Feb; 18(2):125-7. PubMed ID: 8062531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD127371) and fleroxacin (Ro 23-6240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates.
    Jones RN; Johnson DM
    Diagn Microbiol Infect Dis; 1995 Apr; 21(4):209-13. PubMed ID: 7554803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin.
    Barry AL; Fuchs PC; Citron DM; Allen SD; Wexler HM
    J Antimicrob Chemother; 1993 Jun; 31(6):893-900. PubMed ID: 8395494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activities of clinafloxacin, alone and in combination with other compounds, against 45 gram-positive and -negative organisms for which clinafloxacin MICs are high.
    Clark CL; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2295-8. PubMed ID: 10471582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
    Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of clinafloxacin against fluoroquinolone resistant Spanish clinical isolates.
    López-Brea M; Prieto N; Domingo D; de las Cuevas C; Sánchez I; Alarcón T
    Int J Antimicrob Agents; 1999 Jun; 12(1):33-9. PubMed ID: 10389645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin.
    Harrington GD; Zarins LT; Ramsey MA; Bradley SF; Kauffman CA
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):27-31. PubMed ID: 7789094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of E-3846, a new fluoroquinolone, against gram-negative and gram-positive bacteria.
    Moros M; Coll R; Esteve M; Parés J; Xicota MA
    Chemioterapia; 1987 Jun; 6(2 Suppl):149-51. PubMed ID: 3509373
    [No Abstract]   [Full Text] [Related]  

  • 20. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL; Fuchs PC
    J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.